AUSTIN, Texas, Aug. 5, 2025 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and a company of Centene (NYSE: CNC), announced today it invested $18 million in over-the-counter (OTC) items, a Value-added Service (VAS), for members enrolled in either Medicaid or Children's Health Insurance Program (CHIP) from 2020 through 2024. Value-added Services are extra benefits that help provide additional support for low-income families and individuals across all 254 Texas counties.
"The extra benefits we provide our members are critical in supporting their overall health and well-being," said Mitch Wasden, CEO of Superior HealthPlan. "Over the years, we've learned how impactful these over-the-counter items can be to the families we serve, and we're proud to be able to help them fill this need."
As a Superior HealthPlan Value-added Service*, STAR, CHIP, STAR Kids, STAR Health, and some STAR+PLUS members can receive either $25 or $30 for commonly used OTC items every quarter, per member. These include hundreds of items, such as:
Over-the-counter items are just one of the many VAS offerings from Superior. Some members, depending on the program, may also receive:
Value-added Services are updated annually, with new offerings planned for September 1, 2025. To see a list of available OTC items, visit SuperiorHealthPlan.com/OTC.
*Restrictions and limitations may apply.
About Superior HealthPlan
For more than 25 years, Superior HealthPlan has offered high-quality health care to Texans, and is now a leading managed care company providing services to 2 million people. Committed to transforming the health of the communities we serve, one person at a time, Superior supports active local involvement in all 254 Texas counties with 3,500 employees throughout the state. Since 2020, Superior has contributed $11.9 million in grants, sponsorships and employee giving, helping support low-income communities. Superior is a company of Centene, a leading healthcare enterprise that is committed to helping people live healthier lives. For more information, visit www.SuperiorHealthPlan.com.

| Last Trade: | US$33.19 |
| Daily Change: | 0.04 0.12 |
| Daily Volume: | 13,793,651 |
| Market Cap: | US$16.300B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load